Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients

Au, Wing‐Yan; Pang, Annie; Choy, Carolyn; Chim, C.S.; Kwong, Yok–Lam

doi:10.1182/blood-2003-12-4197

Cited by 275 publications

(226 citation statements)

References 27 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…There is circulating EBV DNA and evidence that patients with higher titers have a poorer prognosis [35]. Patients with local/regional disease involving the nose and nasal sinuses have the best outlook, whereas patients who present in other sites and have wide-spread disease have an extremely poor outlook with therapies applied to date [36].…”

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

Background: T‐cell lymphomas make up approximately 10%–15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T‐cell lymphoma (PTCL) is usually made using the World Health Organization classification. The ability of hematopathologists to reproducibly diagnosis aggressive PTCL is lower than that for aggressive B‐cell lymphomas, with a range of 72%–97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography scans seem to be useful as they are in aggressive B‐cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large‐cell lymphoma—particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk‐Adapted Therapy: Anaplastic large‐cell lymphoma is the only subgroup to have a good response to a CHOP‐like regimen. Angioimmunoblastic T‐cell lymphoma has a prolonged disease‐free survival in only ∼20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL‐not otherwise specified is not one disease. Anthracycline‐containing regimens have disappointing results, and a new approach is needed. Natural killer/T‐cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy‐containing regimens. Enteropathy‐associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy‐associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 90:666–673, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Nk/t-cell Lymphomamentioning

confidence: 99%

The aggressive peripheral T‐cell lymphomas: 2015

Armitage

2015

American J Hematol

View full text Add to dashboard Cite

show abstract

“…Plasma EBV DNA was reported to be significantly increased in patients with EBV-positive T-cell and NK-cell lymphomas [42]. Indeed, EBV association is clearly noted in some T-cell and NK-cell LPD/lymphomas [43,44].…”

Section: Pathological Findingsmentioning

confidence: 99%

Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection

et al. 2005

View full text Add to dashboard Cite

Since the initial report of unusual manifestations possibly associated with chronic active Epstein‐Barr virus (EBV) infection (CAEBV), nearly three decades have passed. During this period, reported cases with this entity have dramatically increased in the world. Additionally, recent development of diagnostic procedures, including molecular biological and immunological techniques, have provided us with the ability to define certain diseases, especially malignant disorders. Guidelines, derived mainly from the current literature and recent experiences with CAEBV in Japan, for diagnosing CAEBV are proposed to clarify this enigmatic disease. Am. J. Hematol. 80:64–69, 2005. © 2005 Wiley‐Liss, Inc.

show abstract

“…The incidence of ENKTL parallels the geographic distribution of EBV infection, and the EBVencoded early small RNAs (EBERs) are uniformly detected in the tumour cells (Arber et al, 1993;Kanavaros et al, 1993;Chan et al, 1994Chan et al, , 1997van Gorp et al, 1994;ElenitobaJohnson et al, 1998;Quintanilla-Martinez et al, 1999). In addition, a high level of circulating plasma EBV DNA in patients with ENKTL has correlated with a high tumour burden and inferior survival (Au et al, 2004). These observations suggest that EBV infection is directly involved in the development of ENKTL.…”

Section: Racial Patterns Of Nk/t Cell Lymphoma ª 2011 Blackwell Publimentioning

confidence: 99%

“…These observations suggest that EBV infection is directly involved in the development of ENKTL. Additionally, recent studies suggest that lifestyle factors and environmental exposures, such as occupational exposure to pesticides and solvents, may be risk factors for the disease (Au et al, 2004;Aozasa et al, 2008). In parallel, investigators have identified genetic features that may be important in this disease.…”

Section: Racial Patterns Of Nk/t Cell Lymphoma ª 2011 Blackwell Publimentioning

confidence: 99%

Racial patterns of extranodal natural killer/T‐cell lymphoma, nasal type, in California: a population‐based study

Chang

Fish

et al. 2011

Br J Haematol

View full text Add to dashboard Cite

SummaryIn order to investigate whether the clinical behaviour of extranodal natural killer/T‐cell lymphoma, nasal type (ENKTL) varies by race within a geographic region, we identified a total of 213 non‐Hispanic whites, Hispanics and Asians/Pacific islanders (APIs) diagnosed with ENKTL in the California Cancer Registry between 2001 and 2008. The incidence and outcomes of the disease in these racial groups were analysed. The incidence rates in non‐Hispanic whites, Hispanics and APIs were 0·05, 0·18 and 0·23 per 100 000 person‐years, respectively, among males; and 0·03, 0·07 and 0·10 per 100 000 person‐years, respectively, among females. The overall survival (OS) at 5 years was 28·6% in non‐Hispanic whites, 30·4% in Hispanic, and 24·0% in APIs. In multivariate analysis, distant versus local/regional disease (Hazard Ratio [HR] = 2·01, 95% confidence interval [CI]: 1·36, 2·96), initial treatment with chemotherapy plus radiotherapy (HR = 0·39, 95% CI: 0·22, 0·70) or radiotherapy alone (HR = 0·48, 95% CI: 0·23, 0·99) versus no therapy were associated with OS. However, OS was not affected by age, sex, race, chemotherapy alone, socioeconomic status, or human immunodeficiency virus infection. In conclusion, ENKTL is more common and clinically more similar among Hispanics and APIs than non‐Hispanic whites with poor outcome in all racial groups.

show abstract

Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients

Cited by 275 publications

References 27 publications

The aggressive peripheral T‐cell lymphomas: 2015

The aggressive peripheral T‐cell lymphomas: 2015

Proposed guidelines for diagnosing chronic active Epstein‐Barr virus infection

Racial patterns of extranodal natural killer/T‐cell lymphoma, nasal type, in California: a population‐based study

Contact Info

Product

Resources

About